Evidence map›Paper›PMID 42326820›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Spatially resolved T cell receptor tracking reveals γδT cell localization to tumor-rich regions in high-risk neuroblastoma: A Report from the Children's Oncology Group.

Yiyue Jiang, Wenbao Yu, Yanan Wang, Anusha Thadi, Stephanie Pedersen, Jenna Eagles, Arlene Naranjo, Natalie Collins, Steven G DuBois, Rochelle Bagatell and 3 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yiyue JiangPrincess Margaret Cancer Centre, University Health Network, Toronto ON, Canada.ORCID 0000-0001-5488-9763
Wenbao YuDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0001-8860-2644
Yanan WangPrincess Margaret Cancer Centre, University Health Network, Toronto ON, Canada.ORCID 0000-0003-4947-8665
Anusha ThadiDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Stephanie PedersenPrincess Margaret Cancer Centre, University Health Network, Toronto ON, Canada.
Jenna EaglesPrincess Margaret Cancer Centre, University Health Network, Toronto ON, Canada.
Arlene NaranjoUniversity of Florida, Gainesville FL, USA.ORCID 0000-0001-7737-4324
Natalie CollinsDana-Farber / Boston Children's Cancer and Blood Disorders Program and Department of Pediatrics, Harvard Medical School, Boston MA, USA.ORCID 0000-0003-2980-9244
Steven G DuBoisDana-Farber / Boston Children's Cancer and Blood Disorders Program and Department of Pediatrics, Harvard Medical School, Boston MA, USA.ORCID 0000-0003-0882-738X
Rochelle BagatellDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0002-5729-8819
Brian D CromptonDana-Farber / Boston Children's Cancer and Blood Disorders Program and Department of Pediatrics, Harvard Medical School, Boston MA, USA.ORCID 0000-0001-9404-6621
Kai TanDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0002-9104-5567
Trevor J PughPrincess Margaret Cancer Centre, University Health Network, Toronto ON, Canada.ORCID 0000-0002-8073-5888

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Shared Resource Core 2: Clinical Artificial Intelligence CoreU54CA274516 · NCI · DANA-FARBER CANCER INST · PI DAPHNE A. HAAS-KOGAN · 2023 to 2026
$8.1M
NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U54 CA274516
6 · The paper itself

Abstract

High-risk neuroblastoma (HRNB) is a leading cause of pediatric cancer death. Current therapies center on intensive multimodal treatment including anti-GD2 therapy, with growing interest in harnessing T cell-mediated immunity. How T cells and their receptors (T-cell receptors, TCRs) are spatially organized and function within tumors remains poorly defined. To assess whether intratumoral location influences clonotype-specific T cell states, we profiled TCR repertoires across blood and tumor samples from 37 patients with HRNB using longitudinal bulk TCR sequencing. In a nested subset of 5 patients with paired pre- and post-therapy tumors, we integrated spatial transcriptomics with

Identifiers

PMID42326820
PMCPMC13278277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.